See more : Marvel Gold Limited (GRXMF) Income Statement Analysis – Financial Results
Complete financial analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corbus Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Radisson Mining Resources Inc. (RMRDF) Income Statement Analysis – Financial Results
- Bio-View Ltd (BIOV.TA) Income Statement Analysis – Financial Results
- The Container Store Group, Inc. (TCS) Income Statement Analysis – Financial Results
- Cartier Silver Corporation (CRTID) Income Statement Analysis – Financial Results
- F8 Enterprises (Holdings) Group Limited (8347.HK) Income Statement Analysis – Financial Results
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 881.71K | 3.94M | 36.14M | 4.82M | 2.44M | 1.91M | 648.38K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 31.17M | 1.49M | 1.64M | 98.27K | 89.60K | 48.61M | 26.04M | 15.44M | 5.89M | 1.26M | 0.00 | 0.00 |
| Gross Profit | -31.17M | -1.49M | -757.53K | 3.84M | 36.05M | -43.79M | -23.60M | -13.53M | -5.24M | -1.26M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | -85.92% | 97.50% | 99.75% | -908.11% | -967.09% | -707.60% | -808.21% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.17M | 16.14M | 36.45M | 98.27M | 89.60M | 48.61M | 26.04M | 15.44M | 5.89M | 1.26M | 210.67K | 575.09 |
| General & Administrative | 13.91M | 18.70M | 20.43M | 28.48M | 23.64M | 12.96M | 8.96M | 6.46M | 3.61M | 1.39M | 346.61K | 289.05 |
| Selling & Marketing | -641.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.27M | 18.70M | 20.43M | 28.48M | 23.64M | 12.96M | 8.96M | 6.46M | 3.61M | 1.39M | 346.61K | 289.05 |
| Other Expenses | -30.53M | -48.77K | 11.90M | 13.27M | 4.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.91M | 34.84M | 56.87M | 126.75M | 113.25M | 61.57M | 35.00M | 21.90M | 9.50M | 2.65M | 557.28K | 827.22 |
| Cost & Expenses | 45.08M | 34.84M | 56.87M | 126.75M | 113.25M | 61.57M | 35.00M | 21.90M | 9.50M | 2.65M | 557.28K | 827.22 |
| Interest Income | 0.00 | 0.00 | 1.83K | 1.03K | 1.23M | 982.78K | 183.11K | 477.00 | 3.42K | 2.12K | 754.00 | 59.74 |
| Interest Expense | 2.92M | 2.13M | 1.83M | 1.03M | 19.03K | 0.00 | 183.11K | 0.00 | 2.44K | 24.02K | 45.11K | 0.00 |
| Depreciation & Amortization | 641.00K | 1.49M | 1.64M | 1.69M | 1.23M | 493.94K | 255.65K | 87.66K | 43.94K | 10.41K | 754.00 | 824.15 |
| EBITDA | -44.44M | -38.73M | -54.97M | -121.69M | -76.37M | -56.25M | -32.31M | -19.90M | -8.81M | -2.64M | -556.52K | -62.81 |
| EBITDA Ratio | 0.00% | 0.00% | -6,381.74% | -3,101.40% | -212.89% | -1,178.71% | -1,332.72% | -1,040.23% | -1,358.20% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.08M | -39.84M | -55.99M | -122.81M | -77.10M | -56.75M | -32.56M | -19.99M | -8.85M | -2.65M | -557.28K | -824.15 |
| Operating Income Ratio | 0.00% | 0.00% | -6,350.09% | -3,119.20% | -213.33% | -1,176.78% | -1,334.43% | -1,045.56% | -1,365.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 473.99K | -2.51M | 10.35M | 11.54M | 5.65M | 1.08M | 141.20K | -13.62K | 2.95K | 106.69K | -45.07K | -62.81 |
| Income Before Tax | -44.60M | -42.35M | -45.64M | -111.27M | -71.45M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602.35K | -886.96 |
| Income Before Tax Ratio | 0.00% | 0.00% | -5,176.38% | -2,826.08% | -197.69% | -1,154.48% | -1,328.65% | -1,046.27% | -1,365.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.49M | -87.84K | 35.05K | -2.30M | 1.08M | -396.86K | 13.62K | 2.44K | 24.02K | 44.36K | -62.81 |
| Net Income | -44.60M | -55.83M | -45.55M | -111.30M | -69.15M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602.35K | -886.96 |
| Net Income Ratio | 0.00% | 0.00% | -5,166.42% | -2,826.97% | -191.33% | -1,154.48% | -1,328.65% | -1,046.27% | -1,365.05% | 0.00% | 0.00% | 0.00% |
| EPS | -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.30 | -19.38 | -14.58 | -8.47 | -3.78 | -0.70 | -3.82 |
| EPS Diluted | -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.30 | -19.38 | -14.58 | -8.47 | -3.78 | -0.70 | -3.82 |
| Weighted Avg Shares Out | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M | 1.90M | 1.67M | 1.37M | 1.05M | 672.00K | 860.06K | 232.00 |
| Weighted Avg Shares Out (Dil) | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M | 1.90M | 1.67M | 1.37M | 1.05M | 672.00K | 860.06K | 232.16 |
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
Corbus: Assessing If Lenabasum Can Finally Break Through
The Week Where New York Legalizes Recreational Marijuana
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade
Earnings Previews: Corbus Pharmaceuticals, Yalla
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Source: https://incomestatements.info
Category: Stock Reports